Picture of Innocan Pharma logo

INNO Innocan Pharma Cashflow Statement

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Innocan Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-10.1-3.89-4.25-0.262-0.341
Depreciation
Non-Cash Items4.39-1.681.1-0.1490.523
Unusual Items
Other Non-Cash Items
Changes in Working Capital-0.969-0.531-0.793-1.20.271
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities-6.63-6.07-3.9-1.580.495
Capital Expenditures-0.041-0.026-0.046-0.015-0.016
Purchase of Fixed Assets
Other Investing Cash Flow Items-0.007-0.005-0.0380.0690.001
Other Investing Cash Flow
Cash from Investing Activities-0.048-0.031-0.0840.054-0.015
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities15.30.1252.922.71.15
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash8.71-6.1-1.061.121.68